Logo

Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard

Share this
Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard

Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard

Shots:

  • Exact & Mayo has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening- incidence- and mortality rates. The Voyage study will provide additional- real-world evidence demonstrating the clinical impact of Cologuard & position it as SoC in colorectal cancer screening
  • The Voyage study is a prospective- observational study- enrolling 150-000+ people with a valid Cologuard order and follow them for at least seven years to evaluate clinical outcomes
  • Cologuard is the only FDA-approved- at-home colorectal cancer screening test having the potential to improve screening rates in patients with colorectal cancer and has received FDA’s approval in Aug’14

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions